SCM
OCUL icon

Sterling Capital Management’s Ocular Therapeutix OCUL Stock Holding History

Sterling Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.9K Buy
1,318
+97
+8% +$879 ﹤0.01% 2087
2026
Q1 		$10.3K Buy
1,221
+21
+2% +$200 ﹤0.01% 2359
2025
Q4 		$14.6K Buy
1,200
+859
+252% +$10.4K ﹤0.01% 2411
2025
Q3 		$3.99K Buy
341
+1
+0.3% +$12 ﹤0.01% 2833
2025
Q2 		$3.15K Buy
340
+166
+95% +$1.3K ﹤0.01% 2760
2025
Q1 		$1.27K Buy
174
+16
+10% +$123 ﹤0.01% 2732
2024
Q4 		$1.35K Hold
158
– – ﹤0.01% 2875
2024
Q3 		$1.38K Buy
+158
New +$1.3K ﹤0.01% 2374

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sterling Capital Management's OCUL Position: Q2 2026 in Review

Sterling Capital Management increased its Ocular Therapeutix (OCUL) stake by 7.9% in Q2 2026, buying an estimated $879 and bringing the position to 1,318 shares worth $12.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2087.

Sterling Capital Management first reported a position in OCUL in Q3 2024 and has held it in 8 quarters since. The position peaked at $14.6K in Q4 2025. 263 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Sterling Capital Management held 1,318 shares of Ocular Therapeutix worth $12.9K as of Q2 2026.
  • Sterling Capital Management bought 97 Ocular Therapeutix shares in Q2 2026, an estimated $879.
  • Ocular Therapeutix made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2087 holding.
  • Sterling Capital Management first reported a position in Ocular Therapeutix in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's Ocular Therapeutix position peaked at $14.6K in Q4 2025.
  • 263 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.